Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
2.
Br J Haematol ; 121(1): 187-9, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12670352

ABSTRACT

Desferrioxamine (DFX) alone (40-50 mg/kg/d s.c. over 8-12 h, five times weekly) was compared with combined DFX twice weekly and deferiprone (75 mg/kg/d) over 12 months in previously poorly chelated thalassaemia patients. Serum ferritin fell from 5506 +/- 635 microg/l (mean +/- SEM) to 3998 +/- 604 microg/l (P < 0.001; n = 14) in the DFX group and from 4153 +/- 517 microg/l to 2805 +/- 327 microg/l in the combined group (P < 0.01; n = 11). Deferiprone plus DFX produced a greater mean urine iron excretion (1.01 mg/kg/24 h) than iron intake from blood transfusion in each patient. Main side-effects were skin reactions (DFX alone), nausea and arthralgia (combined therapy). As chelation therapy, the combined protocol was as effective as DFX five times weekly.


Subject(s)
Chelating Agents/therapeutic use , Deferoxamine/therapeutic use , Iron Overload/drug therapy , Iron , Pyridones/therapeutic use , beta-Thalassemia/drug therapy , Adolescent , Adult , Blood Transfusion , Child , Deferiprone , Drug Administration Schedule , Drug Therapy, Combination , Female , Ferritins/blood , Ferritins/urine , Humans , Iron Overload/blood , Iron Overload/urine , Male , Statistics, Nonparametric , beta-Thalassemia/metabolism , beta-Thalassemia/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...